Diarrhea News and Research

Latest Diarrhea News and Research

Researchers aim to develop vaccine for 'traveler's diarrhea'

Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ETEC.

26 Sep 2018

Increased physical activity associated with improvement in IBS symptoms

Increased physical activity is now being emphasized as a treatment option for the gastric intestinal disease known as IBS. Research at Sahlgrenska Academy, Sweden, indicates improvements in both intestinal function and self-esteem of patients who exercise more.

25 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea

One man's trash is another man's treasure, as the saying goes. If things go to plan, feces from registered and thoroughly tested healthy donors will in a few years be the standard treatment for the bacterium Clostridium difficile at Danish hospitals.

21 Sep 2018

Insulin treatment shows great potential against chronic bowel inflammation

Millions of people take insulin every day to treat their diabetes. But diabetes is not the only disease on which insulin has an effect, it appears.

21 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Bacteria in the gut found to produce electricity

Researchers have discovered hundreds of bacterial species, including those in the human gut, that can generate electricity.

13 Sep 2018

New insight on mechanics of rotavirus could open up avenues for effective treatments

Researchers have provided new insight on the mechanics of a virus that causes severe diarrhea and sickness in young children, according to a report published in eLife.

12 Sep 2018

New paper reports conserved collateral susceptibility to antibiotics in E. coli

LSTM's Dr Adam Roberts is a co-author on a new paper published in Nature Communications which reports conserved collateral susceptibility to antibiotics in the human pathogen Escherichia coli.

10 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Fiber strengthens intestinal barrier and counteracts gastrointestinal problems

Similar to patients with Crohn's disease, elderly people with stomach problems have a intestinal barrier that is not functioning optimally.

7 Sep 2018

Cryptosporidiosis worsened by commonly used probiotic

Researchers have found that infection with the intestinal parasite Cryptosporidium parvum is worsened in mice that have been administered a probiotic.

31 Aug 2018

Newborns require special diagnosis and treatment considerations for C. difficile infection

Newborns require special diagnosis and treatment considerations for an infectious diarrhea known as Clostridioides difficile infection, according to a new evidence-based white paper published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

31 Aug 2018

Diarrhea News and Research

Latest Diarrhea News and Research

Researchers aim to develop vaccine for 'traveler's diarrhea'

Increased physical activity associated with improvement in IBS symptoms

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea

Insulin treatment shows great potential against chronic bowel inflammation

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Bacteria in the gut found to produce electricity

New insight on mechanics of rotavirus could open up avenues for effective treatments

New paper reports conserved collateral susceptibility to antibiotics in E. coli

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Fiber strengthens intestinal barrier and counteracts gastrointestinal problems

Cryptosporidiosis worsened by commonly used probiotic

Newborns require special diagnosis and treatment considerations for C. difficile infection

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Diarrhea News and Research

Latest Diarrhea News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in